drugset / Trial / NCT03949764
The Kentucky Viral Hepatitis Treatment Study
Phase 4
Completed
374 enrolled
Jennifer Havens
Gilead Sciences · collabIcahn School of Medicine at Mount Sinai · collabNational Cancer Institute (NCI) · collabNational Institute on Drug Abuse (NIDA) · collabUniversity of Bristol · collabUniversity of Kentucky · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the opioid/hepatitis C (HCV) syndemic. KeY Treat is a clinical research study seeking to determine whether removing barriers (cost, insurance, specialist, abstinence) associated with accessing direct-acting antivirals (DAAs) for the treatment of HCV will impact health in Perry County, Kentucky.
Timeline
- Start
- 2019-09-23
- Primary completion
- 2025-06-30
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sofosbuvir/velpatasvir | Unknown | — | — |